Job title: Senior Global Project Head
Dr. Baisong Mei has 20 years of experience in clinical development, discovery research, and CMC development in pharmaceutical industry, and worked on multiple drug candidates including 5 approved by Regulatory authorities. Baisongjoined Sanofi Development in 2017 as Senior Global Project Head and responsible for Clinical Development of Fitusiran and other rare disease candidates on pipeline. Prior to joining Sanofi, Baisong was the Therapeutic Area Head for Hematology Clinical Development at Biogen, leading non-malignant hematology clinical development, including early and late stage programs for hemophilia and hemoglobinopathies. Before working in clinical development, Baisong was a director of Hematology Research in Biogen, and was leading CMC Process Development and Discovery Research groups in Bayer.
Panel Discussion: Defining & Evaluating the Future of RNAi-Based Therapeutics 1:30 pm
What are the important steps needed to select and drug ‘undruggable’ targets beyond the liver? How does the field ensure success of RNAi drug candidates in clinical trials? Are we looking into a future where RNAi-based therapeutics replicate the success of small molecules and antibodies?Read more
day: Day Two
Fitusiran: A Novel siRNA Therapy for Treatment of Hemophilia A & Hemophilia B, with or without Inhibitors 9:00 am
Fitusiran is a novel siRNA therapy targeting antithrombin in the coagulation cascade to rebalance hemostasis in patients with haemophilia A and haemophilia B, with or without inhibitors GalNAc mediated liver targeted delivery allows monthly subcutaneous administration Fitusiran is under Phase 3 clinical developmentRead more
day: Day Two